Our use of cookies

We use cookies so that we can improve the experience for visitors to our websites. This includes cookies that are necessary for the operation of our websites, as well as other cookies used for analytics purposes. We will not use analytical cookies unless you enable them.

For more information about our use of cookies, please refer to our our cookie policy.


Analytics cookies

These cookies allow us to understand how our websites are used, and to improve our websites over time.

:


What We Support

Thank you for your interest in the Indivior Independent Medical Education Grants Program.

Independent Medical Education – Indivior provides support to accredited educational programs and activities in the United States that provide for increased understanding of scientific, clinical and healthcare issues related to Indivior's education areas of interest. Requests for support for non-accredited programs and activities will not be considered.

Indivior will consider requests for funding with regard to the following education areas of interest:

  • Opioid Use Disorder (OUD)
  • Opioid Overdose Treatment

Before submitting a request, please review the information provided on the Overview, Grants Process, and Request a Grant pages. Questions should be directed by email to educationalgrants@indivior.com.

This information pertains only to organizations based in the United States.

Education Areas of Interest

Top view brain outline

  • Standard of care for the treatment of OUD as reflected in current and evidence-based updates to guidelines
  • Awareness of current guidelines for the treatment of OUD
  • Optimal therapeutic management and treatment of patients with OUD including education
  • Rationale for use of a partial opioid agonist for the treatment of OUD
  • Awareness of substance use disorders including OUD
  • Optimizing treatment/treatment strategies across the treatment continuum (i.e., initiation, maintenance, cessation/long term management)
  • Improving treatment adherence, relapse, overdose, and abuse/misuse/diversion
  • Recognizing the barriers to the treatment of OUD
  • Evaluation in sub-populations, patients at risk, and underserved patients
  • Long term treatment outcomes in patients with OUD (including real-world evidence, quality of life and health economic assessments)
  • Access challenges: patients in the criminal justice system, geographic (e.g., rural areas where travel is a challenge to health care), homelessness (e.g., mobile health)
  • Access challenges within health systems/integrated delivery networks (IDNs)
  • Clinical or healthcare issues related to OUD
  • Social determinants of health (SDoH) and utilization of extended-release medications for OUD
  • Continuity of care during the COVID-19 pandemic (e.g., telemedicine)
Blue blus sign with a dark blue atom-like shape in the background

  • Overcoming barriers to treatment (e.g., access, funding, stigma) and sharing successful strategies to treat opioid overdoses
  • Signs, symptoms, and treatment of opioid overdose; understanding the evolution of the opioid crisis and the role of synthetic opioids
  • Pharmacological approaches for the treatment of opioid overdose
  • Strategies to reduce the risk of overdose and manage individuals post-overdose
  • Strategies to encourage and optimize the participation of first responders (e.g., emergency medical services, law enforcement) in the treatment of opioid overdose
  • Health-economic impact of nonfatal opioid overdose
  • Comorbidities associated with non-fatal opioid overdose (e.g., duration of hypoxia)
  • Strategies for transitioning to a medication for opioid use disorder treatment following an opioid overdose